mRNA 1325

Drug Profile

mRNA 1325

Alternative Names: mRNA-1325; Zika mRNA vaccine- Moderna Therapeutics

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Moderna Therapeutics
  • Class RNA; RNA vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Zika virus infection

Most Recent Events

  • 01 Dec 2016 Phase-I/II clinical trials in Zika virus infection (Prevention) in USA (Parenteral) (NCT03014089)
  • 01 Sep 2016 Moderna Therapeutics receives grant from Biomedical Advanced Research and Development Authority for mRNA 1325 development in Zika virus infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top